BRAF — B-Raf Proto-Oncogene, Serine/Threonine Kinase

BRAF — B-Raf Proto-Oncogene, Serine/Threonine Kinase

Pathway Diagram

```mermaid
flowchart TD
BRAF["BRAF<br/>Serine/Threonine Kinase"]
KIAA1549["KIAA1549<br/>Fusion Partner"]
MAPK["MAPK Pathway<br/>Cell Signaling"]
ERK["ERK1/2<br/>Downstream Effectors"]

Neurodegeneration["Neurodegeneration<br/>Disease Process"]
ALS["Amyotrophic Lateral<br/>Sclerosis (ALS)"]
MS["Multiple Sclerosis<br/>(MS)"]

Glioma["Glioma<br/>Brain Tumor"]
Glioblastoma["Glioblastoma<br/>Aggressive Brain Tumor"]
PLGG["Pediatric Low-Grade<br/>Gliomas"]

Cell_Proliferation["Cell Proliferation<br/>and Survival"]
Senescence["Cellular<br/>Senescence"]
Apoptosis["Programmed<br/>Cell Death"]

Therapeutic_Target["BRAF Inhibitors<br/>Targeted Therapy"]

KIAA1549 -->|"fusion creates"| BRAF
BRAF -->|"activates"| MAPK
MAPK -->|"phosphorylates"| ERK
ERK -->|"promotes"| Cell_Proliferation

BRAF -->|"biomarker for"| Neurodegeneration
BRAF -->|"activates"| ALS
BRAF -->|"activates"| MS

BRAF -->|"drives"| Glioma
BRAF -->|"associated with"| Glioblastoma
BRAF -->|"biomarker for"| PLGG

Cell_Proliferation -->|"leads to"| Glioma
BRAF -->|"induces"| Senescence
Senescence -->|"triggers"| Apoptosis

Therapeutic_Target -->|"inhibits"| BRAF
Therapeutic_Target -->|"targets"| Glioblastoma
Therapeutic_Target -->|"treats"| ALS

style BRAF fill:#006494
style Therapeutic_Target fill:#1b5e20
style MAPK fill:#4a1a6b
style ERK fill:#4a1a6b
style Neurodegene

BRAF — B-Raf Proto-Oncogene, Serine/Threonine Kinase

Pathway Diagram

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">B-Raf Proto-Oncogene, Serine/Threonine Kinase</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>BRAF</td></tr>
<tr><td><strong>Full Name</strong></td><td>B-Raf Proto-Oncogene, Serine/Threonine Kinase</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>7q34</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>673</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000157764</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>P15056</td></tr>
<tr><td><strong>OMIM ID</strong></td><td>164757</td></tr>
<tr><td><strong>Protein Length</strong></td><td>766 amino acids</td></tr>
<tr><td><strong>Protein Family</strong></td><td>RAF family, MAP kinase kinase kinases</td></tr>
<tr><td><strong>Aliases</strong></td><td>RAF1, B-Raf, p94</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Melanoma, Cardiofaciocutaneous Syndrome, Noonan Syndrome</td></tr>
</table>
</div>

Overview

BRAF (B-Raf proto-oncogene, serine/threonine kinase) is the most potent member of the RAF family of serine/threonine protein kinases that function as critical components of the [RAS-RAF-MEK-ERK (MAPK) signaling pathway](/mechanisms/mapk-signaling-pathway). BRAF is the strongest activator of MEK1/2 among the three RAF isoforms (ARAF, BRAF, RAF1) due to its higher basal kinase activity and less stringent activation requirements [@braf_mapk_pathway].

In the central nervous system, BRAF plays essential roles in [neuronal development](/cell-types/neurons), [synaptic plasticity](/mechanisms/synaptic-plasticity), memory formation, and cellular stress responses. Dysregulation of BRAF signaling is implicated in [neurodegenerative diseases](/diseases/alzheimers-disease) including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease), as well as various cancers, particularly [melanoma](/diseases/melanoma) where the V600E mutation is the most common oncogenic driver [@braf_melanoma].

Protein Structure and Function

Domain Architecture

BRAF contains several functional domains [@braf_structure]:

BRAF Protein Structure

N-terminus ───────────────────────────────────────── C-terminus
│ │ │ │
▼ ▼ ▼ ▼
┌──────┐ ┌─────────┐ ┌─────────┐ ┌─────────┐
│CR1 │ │ CR2 │ │ CR3 │ │Kinase │
│Region │ │ regulatory│ │ C3 │ │Domain │
└──────┘ └─────────┘ └─────────┘ └─────────┘
│ │ │ │
│ │ │ │
S/T rich Phosphorylation Zinc finger Catalytic
domain sites (S151, domain kinase
T598, S729) activity

• CR1 (Conserved Region 1): Contains the RAS-binding domain (RBD) and cysteine-rich domain
• CR2 (Conserved Region 2): Regulatory region with phosphorylation sites
• CR3 (Conserved Region 3): Contains the activation segment and kinase domain
• Kinase domain: Catalytic serine/threonine kinase activity

Activation Mechanism

BRAF activation requires multiple steps [@braf_phosphorylation][@braf_structure]:

RAF Isoform Specificity

| Feature | BRAF | RAF1 (CRAF) | ARAF |
|---------|------|-------------|------|
| Kinase activity | Highest | Intermediate | Lowest |
| MEK activation | Potent | Moderate | Weak |
| Dimerization | Strong | Strong | Weak |
| Neuronal expression | High | High | Lower |
| Oncogenic potential | High | Low | Low |

Role in Neurodegeneration

Alzheimer's Disease

BRAF/MAPK signaling is dysregulated in AD through multiple mechanisms [@braf_alzheimer][@braf_mapk_tau]:

The balance between physiological BRAF signaling (required for memory) and pathological overactivation (causing neurodegeneration) is critical.

Parkinson's Disease

In PD, BRAF contributes to disease pathogenesis through [@braf_parkinson]:

Other Neurodegenerative Conditions

• Huntington's Disease: MAPK activation mediates mutant huntingtin toxicity
• Amyotrophic Lateral Sclerosis (ALS): BRAF signaling in motor neuron degeneration
• Frontotemporal Dementia: MAPK dysregulation in tauopathies
• Multiple Sclerosis: MAPK in demyelination and gliosis

Role in Neuronal Function

Synaptic Plasticity and Memory

BRAF-mediated MAPK signaling is crucial for synaptic plasticity [@braf_synapse][@braf_neuronal_survival]:

BRAF in Synaptic Plasticity

Neurotrophic factor (BDNF, NGF)
│
▼
RTK activation
│
▼
RAS-GTP formation
│
▼
RAF activation (BRAF/RAF1)
│
▼
MEK1/2 activation
│
▼
ERK1/2 activation
│
├──────────► Transcription (CREB)
│ │
│ ▼
│ Synaptic protein synthesis
│ │
│ ▼
│ LTP/LTM formation
│
└──────────► Synaptic remodeling
(actin cytoskeleton)

Neuronal Development

BRAF is essential for neural development [@braf_neuronal_differentiation][@braf_conditional_knockout]:

• Neural progenitor proliferation: MAPK signaling promotes progenitor cell division
• Neuronal differentiation: BRAF activation drives neuronal lineage commitment
• Axon guidance: MAPK in growth cone steering
• Dendrite morphogenesis: BRAF regulates dendritic arborization
• Myelination: Oligodendrocyte differentiation requires MAPK signaling

Stress Response

In neurons, BRAF signaling mediates cellular stress responses:

• Oxidative stress: MAPK activation in response to ROS
• ER stress: Unfolded protein response signaling
• DNA damage: Cell cycle arrest and repair
• Excitotoxicity: Glutamate-induced MAPK activation

Expression Pattern

Brain Expression

BRAF is widely expressed in the central nervous system:

| Region | Expression Level | Cell Types |
|--------|-----------------|-------------|
| [Cortex](/brain-regions/cortex) | High | Pyramidal neurons, interneurons |
| [Hippocampus](/brain-regions/hippocampus) | High | CA1-CA3 pyramidal cells, granule cells |
| [Cerebellum](/brain-regions/cerebellum) | High | Purkinje cells, granule cells |
| [Substantia nigra](/brain-regions/substantia-nigra) | Moderate | Dopaminergic neurons |
| Thalamus | Moderate | Relay neurons |
| Spinal cord | Moderate | Motor neurons, interneurons |

Cellular Distribution

• Neurons: High expression, particularly in somata and dendrites
• [Astrocytes](/cell-types/astrocytes): Moderate expression
• [Oligodendrocytes](/cell-types/oligodendrocytes): Lower expression
• [Microglia](/cell-types/microglia): Activation-induced expression
• Neural progenitor cells: High expression

Therapeutic Implications

MAPK Pathway Modulation

Therapeutic targeting of BRAF in neurodegeneration requires careful consideration [@braf_kinase_inhibitors]:

• Originally developed for melanoma
• Potential for neuroprotective effects in specific contexts
• Blood-brain barrier penetration is limited

• Downstream of BRAF
• May reduce pathological MAPK overactivation
• Better CNS penetration in some cases

• Target downstream effectors
• Potential for neuroprotection

Challenges and Considerations

• Dose-dependent effects: Low-level BRAF signaling is neuroprotective; complete inhibition may be detrimental
• Isoform specificity: BRAF vs. RAF1 inhibition has different outcomes
• Compensatory mechanisms: Pathway redundancy may limit monotherapy efficacy
• Therapeutic window: Narrow margin between beneficial and harmful doses

Gene Therapy Approaches

• RNAi: Selective BRAF knockdown in affected neurons
• CRISPR: Allele-specific editing for gain-of-function mutations
• Viral vectors: Targeted delivery to CNS

Interactions and Pathways

Protein Interactions

| Partner | Interaction Type | Function |
|---------|-----------------|----------|
| [RAS family](/genes/ras) | Activator | Membrane recruitment and activation |
| [RAF1](/genes/raf1) | Dimerization partner | Heterodimer formation |
| [MEK1](/genes/map2k1) | Substrate | Phosphorylation |
| [MEK2](/genes/map2k2) | Substrate | Phosphorylation |
| [14-3-3 proteins](/proteins/14-3-3) | Binding | Sequestration, inactive complex |
| [KSR1/2](/genes/ksr1) | Scaffold | Pathway assembly |

Signaling Cross-talk

• PI3K/AKT pathway: Cross-inhibition with MAPK
• mTOR signaling: Downstream of ERK
• cAMP/PKA pathway: Modulation of RAF activity
• Calcium signaling: Calmodulin-RAF interaction

Mutations and Disease Variants

Cancer-Associated Mutations

The V600E mutation is the most common BRAF oncogenic variant [@braf_melanoma]:

• V600E: Valine to Glutamic acid at position 600
• Constitutive kinase activity
• Found in ~50% of melanomas, 40% of papillary thyroid cancers
• Targeted by vemurafenib, dabrafenib

Developmental Disorders

BRAF germline mutations cause [@braf_cfc_syndrome]:

• Cardiofaciocutaneous (CFC) syndrome: Dysmorphic features, cardiac defects, developmental delay
• Noonan syndrome: Similar phenotype with different genetic basis
• LEOPARD syndrome: Lentigines, ECG abnormalities, hypertrophic cardiomyopathy

Neurodegeneration-Associated Variants

• Altered expression patterns in AD/PD brains
• Rare variants may modify disease risk
• Interaction with other Parkinson's risk genes

Animal Models

Mouse Models

• Braf knockout: Embryonic lethal (E12.5-E15.5)
• Conditional knockouts: Brain-specific deletion reveals developmental roles [@braf_conditional_knockout]
• Transgenic V600E: Melanoma development
• knock-in models: Disease-associated variants

Research Applications

• MAPK pathway studies
• Neurodegeneration models
• Developmental biology
• Cancer research

Biomarkers

BRAF/MAPK activation status:

• Phosphorylated ERK (pERK) as downstream marker
• BRAF V600E mutation testing in cancer
• Expression analysis in disease tissue

See Also

• [MAPK Signaling Pathway](/mechanisms/mapk-signaling-pathway)
• [RAF1](/genes/raf1)
• [MEK1](/genes/map2k1)
• [MEK2](/genes/map2k2)
• [ERK1](/genes/mapk1)
• [ERK3](/genes/mapk3)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Tau Protein](/proteins/tau)

External Links

• [NCBI Gene: BRAF](https://www.ncbi.nlm.nih.gov/gene/673)
• [OMIM: BRAF](https://www.omim.org/entry/164757)
• [Ensembl: BRAF](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157764)
• [UniProt: BRAF](https://www.uniprot.org/uniprot/P15056)
• [GeneCards: BRAF](https://www.genecards.org/cgi-bin/carddisp.pl?gene=BRAF)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving BRAF — B-Raf Proto-Oncogene, Serine/Threonine Kinase discovered through SciDEX knowledge graph analysis: